rs4794067 — TBX21 TBX21 T-bet Promoter -1993T>C

Promoter variant ~1993 bp upstream of TBX21 (encoding the T-bet master transcription factor) that reduces TBX21 expression and blunts Th1-mediated immunity; the C allele is associated with altered Th1/Th2 balance, hypothyroidism susceptibility, and aspirin-induced asthma risk in Asian populations.

See your personal result for TBX21

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

TBX21 T-bet Promoter — The Th1 Dimmer Switch

Your immune system constantly chooses between attack strategies. When a cell is infected by a virus or bacteria, T-bet11 T-bet
T-box transcription factor 21 (TBX21) — the master regulator that drives naïve CD4+ T cells to become interferon-gamma-producing Th1 helpers, the immune system's primary response to intracellular pathogens and autoimmune-prone inflammation tells helper T cells to become Th1 fighters, flooding the tissue with interferon-gamma (IFN-gamma) to kill infected cells. When parasites or allergens appear, a different transcription factor (GATA-3) drives Th2 differentiation instead. rs4794067 sits in the TBX21 promoter — the regulatory region that determines how strongly the gene is switched on — and affects how much T-bet a person's immune cells produce.

This variant was first identified in a 2005 Japanese study of aspirin-induced asthma and has since been studied across more than a dozen independent cohorts, including large GWAS datasets totalling millions of genomes. What has emerged is a complex but consistent picture: rs4794067 modulates the overall setpoint of Th1 immune activity in ways that affect susceptibility to autoimmune, inflammatory, and infectious diseases.

The Mechanism

rs4794067 lies approximately 1,993 base pairs upstream of the TBX21 transcription start site on chromosome 17 (GRCh38: chr17:47,731,462), in a region that controls how much TBX21 mRNA is produced in T cells. The C variant allele alters nuclear protein binding at this site.

A functional study by Fyall et al. (2012)22 functional study by Fyall et al. (2012) directly measured immune cell cytokine output in 210 human blood donors stratified by genotype. CC individuals produced significantly less IFN-gamma (p=0.02) and IL-4 (p=0.001) than TT individuals after mitogen stimulation — effects replicated across two independent batches. The CC genotype essentially runs T-bet at a lower dial setting, blunting the Th1 response without fully eliminating it.

The consequence is a shift in Th1/Th2/Th17 balance: C allele carriers mount weaker IFN-gamma-mediated responses, but with less T-bet to suppress Th17 differentiation, they may compensate with elevated IL-17 activity. The periapical lesion study by Colavite et al. (2019)33 periapical lesion study by Colavite et al. (2019) confirmed this: in C allele carriers, Th17 responses were upregulated at the periapex alongside reduced T-bet/IFN-gamma expression — a mechanistic demonstration of how a single promoter variant reshapes the balance between these two arms of T-cell immunity.

The Evidence

The largest single signal for this variant comes from a 2026 multi-ancestry genome-wide association study by White et al.44 genome-wide association study by White et al. analysing ~2.9 million genomes across 19 biobanks. The C allele at rs4794067 emerged as a genome-wide significant risk locus for primary hypothyroidism (beta 0.055, p=8×10⁻⁴²). Thyroid autoimmunity — the dominant cause of primary hypothyroidism — is a Th1/Th17-driven process; altered T-bet-mediated regulation of these pathways is mechanistically consistent with the observed association.

The variant's original discovery context — aspirin-induced asthma — remains biologically instructive. Akahoshi et al. (2005)55 Akahoshi et al. (2005) found the C allele significantly associated with aspirin-induced asthma (AIA) susceptibility in Japanese subjects. AIA involves dysregulated arachidonic acid metabolism intersecting with aberrant immune polarisation, and the TBX21 promoter variant appears to modulate this susceptibility in the East Asian context where the C allele is rarer (~11%).

At the tissue level, the T allele shows the opposite pattern. The Cavalla et al. (2015) study66 Cavalla et al. (2015) study of 608 Brazilian dental patients found the T allele enriched in chronic periodontitis patients versus gingivitis controls, with T-bet transcripts upregulated in T allele carriers in periodontal tissue. The Li et al. (2024) ankylosing spondylitis study77 Li et al. (2024) ankylosing spondylitis study found that the C allele haplotype (rs4794067/C combined with rs11657479/C) increased risk in HLA-B27-positive individuals — a finding in the opposite direction for AS, where Th17 rather than Th1 is the primary effector axis. Together, these studies illustrate that the same promoter variant modulates risk differently depending on which T-cell effector pathway drives the disease.

A 2021 meta-analysis (Wang et al., PMID 3393819288 Wang et al., PMID 33938192) synthesised the published association data across autoimmune diseases and concluded that both the T and C alleles confer disease risk in a context-dependent manner, with the T allele specifically associated with elevated autoimmune risk in Asian populations through multiple genetic models.

Practical Implications

For C allele carriers, the dominant theme is blunted Th1-mediated immune regulation, with potential downstream effects on thyroid autoimmunity and susceptibility to aspirin-sensitive airway inflammation. The C allele's large-scale GWAS association with hypothyroidism makes thyroid function monitoring the highest-yield clinical application. The blunted IFN-gamma response may also impair clearance of certain intracellular pathogens — hepatitis C virus persistence was studied in one publication (Zhu et al., 2015) in a Chinese population — though this connection requires further replication.

For TT homozygotes, a more active Th1 response is the norm. While this confers stronger Th1-mediated immunity, it can also predispose to Th1-driven inflammatory pathology in mucosal tissues (periodontitis, periapical lesions) where excess T-bet activity sustains local inflammation.

Interactions

The most studied interaction is between rs4794067 and IFNG rs206970599 IFNG rs2069705 — the interferon-gamma promoter variant. Leng et al. (2016) demonstrated a significant genetic interaction between these two variants in a 3,732-subject Chinese SLE cohort: neither variant independently reached significance for SLE, but their combination was associated with disease risk. This is the canonical "T-bet drives IFN-gamma production" axis reflected in genetics — disrupting either end of the signal chain compounds risk.

rs11657479, another TBX21 intronic variant in strong linkage disequilibrium with rs4794067, has been studied in the same ankylosing spondylitis and uveitis datasets. The haplotype formed by these two variants appears to be the functional unit determining TBX21 expression in specific immune contexts.

Genotype Interpretations

What each possible genotype means for this variant.

TT Normal

Common TBX21 genotype with typical Th1 immune balance

You carry two copies of the T allele — the most common genotype in European, African, and East Asian populations. About 53% of people of European descent share this genotype. Your TBX21 promoter region follows the reference pattern, supporting typical T-bet expression and IFN-gamma production from Th1 cells. This variant is not associated with altered hypothyroidism risk or aspirin-induced asthma susceptibility at the population level.

CT Intermediate

One C allele — modestly reduced Th1 output and mildly elevated hypothyroidism risk

The biological basis for this association lies in T-bet's role in regulating the Th1/Th17 balance. Reduced T-bet expression (driven by the C allele) allows more Th17 activity in thyroid tissue. Since autoimmune thyroiditis (Hashimoto's and Graves' disease) involves both Th1 and Th17 effector pathways, a shift in their ratio can alter disease susceptibility and clinical trajectory. The functional study by Fyall et al. (2012) showed CC homozygotes had the largest cytokine reduction; CT heterozygotes had intermediate blunting consistent with the additive inheritance pattern documented for this variant.

CC High Risk

Two C alleles — significantly blunted Th1 response and elevated hypothyroidism risk

The CC genotype at rs4794067 represents full homozygosity for the hypomorphic TBX21 promoter allele. This translates to consistently reduced T-bet-driven transcription in stimulated T cells, with downstream consequences for both IFN-gamma and IL-4 output. The unexpected reduction in IL-4 (a Th2 cytokine) alongside IFN-gamma suggests T-bet's role is not simply to suppress Th2 — at this promoter locus, reduced T-bet affects the overall magnitude of adaptive immune responses, not just the Th1/Th2 ratio.

In the context of thyroid autoimmunity, the mechanistic picture points toward altered Th17 compensation: with less T-bet to restrain Th17 differentiation, CC carriers may have a higher Th17/Th1 ratio in thyroid tissue. Both Hashimoto's thyroiditis and Graves' disease involve Th17 effector function alongside Th1, and the specific balance influences disease phenotype and progression rate.

The aspirin-induced asthma association (originally discovered in Japanese subjects, where the C allele is rare at ~11%) suggests that even modest changes in TBX21 expression can shift airway immune responses in aspirin-sensitive individuals. CC carriers should be particularly attentive to respiratory reactions following NSAID use.